## HALT-2 study : Automatic summary report

Study number of the facility : [ltcf_id_1] | Date of the survey : [ltcf_id_2]
Number of eligible residents : [ltcf_id_3] | Number of completed resident forms : [ltcf_id_4]

INFECTIONS
Total number of residents with signs: [infections_19]
Total number of confirmed infections: [infections_1]
Total number of probable infections: [infections_18]
Total number (%) of infections by site :
| Number | % of total
Urinary tract | [infections_2] | [infections_3]
Skin/Wound | [infections_4] | [infections_5]
Respiratory tract | [infections_6] | [infections_7]
Gastro-intestinal | [infections_8] | [infections_9]
Eye, ear, mouth,.. | [infections_10] | [infections_11]
Systemic infection | [infections_12] | [infections_13]
Unexplained fever | [infections_14] | [infections_15]
Other | [infections_16] | [infections_17]
ANTIMICROBIAL (AM) USE
Total number of residents with AM therapy: [antibiotics_20]
Total number of molecules: [antibiotics_1]
Total number (%) of antimicrobials by class :
|  | Number | % of total
Tetracyclines | (J01A) | [antibiotics_2] | [antibiotics_3]
Amphenicols | (J01B) | [antibiotics_4] | [antibiotics_5]
Beta-lactams | (J01C) | [antibiotics_6] | [antibiotics_7]
Cephalosporins and other beta-lactams | (J01D) | [antibiotics_8] | [antibiotics_9]
Sulfonamides, Trimethoprim | (J01E) | [antibiotics_10] | [antibiotics_11]
Macrolides, lincosamides, streptogramins | (J01F) | [antibiotics_12] | [antibiotics_13]
Aminoglycosides | (J01G) | [antibiotics_14] | [antibiotics_15]
Quinolones | (J01M) | [antibiotics_16] | [antibiotics_17]
Other antimicrobials | (J01X) | [antibiotics_18] | [antibiotics_19]

MICROBIOLOGICAL RESULTS | Number | %
Antimicrobial treatments with microbiological sample | [microorganisms_1] | [microorganisms_2]
Number of culture results reported | [microorganisms_3] |
RESISTANT MICRO-ORGANISMS | Number of isolates
Clostridium difficile | [microorganisms_30]
Staphylococcus aureus (MRSA, Oxacillin-R) | [microorganisms_5]
Acinetobacter baumannii (Carba-R) | [microorganisms_7]
Enterococcus species (Glyco-R) | [microorganisms_9]
Enterobacter species (3rd gen. Cephalo-R) | [microorganisms_11]
Enterobacter species (3rd gen. Cephalo-R AND Carba-R) | [microorganisms_23]
Escherichia coli (3rd gen. Cephalo-R) | [microorganisms_13]
Escherichia coli (3rd gen. Cephalo-R AND Carba-R) | [microorganisms_25]
Klebsiella species (3rd gen. Cephalo-R) | [microorganisms_15]
Klebsiella species (3rd gen. Cephalo-R AND Carba-R) | [microorganisms_27]
Proteus species (3rd gen. Cephalo-R) | [microorganisms_17]
Proteus species (3rd gen. Cephalo-R AND Carba-R) | [microorganisms_29]
Pseudomonas aeruginosa (Carba-R) | [microorganisms_19]

### HALT-2 study : Automatic summary report (page 2)

RESIDENT CHARACTERISTICS
| Total number residents | % total resident population | Residents with signs/symptoms | Residents with AM therapy
> 85 years | [residents_characteristics_31] | [residents_characteristics_1] | [residents_characteristics_2] | [residents_characteristics_3]
Male residents | [residents_characteristics_32] | [residents_characteristics_4] | [residents_characteristics_5] | [residents_characteristics_6]
Urinary catheter | [residents_characteristics_33] | [residents_characteristics_7] | [residents_characteristics_8] | [residents_characteristics_9]
Vascular catheter | [residents_characteristics_34] | [residents_characteristics_10] | [residents_characteristics_11] | [residents_characteristics_12]
Pressure sore | [residents_characteristics_35] | [residents_characteristics_13] | [residents_characteristics_14] | [residents_characteristics_15]
Other wounds | [residents_characteristics_36] | [residents_characteristics_16] | [residents_characteristics_17] | [residents_characteristics_18]
Disorientation | [residents_characteristics_37] | [residents_characteristics_19] | [residents_characteristics_20] | [residents_characteristics_21]
Wheelchair/bedridden | [residents_characteristics_38] | [residents_characteristics_22] | [residents_characteristics_23] | [residents_characteristics_24]
Surgery (30 last days) | [residents_characteristics_39] | [residents_characteristics_25] | [residents_characteristics_26] | [residents_characteristics_27]
Incontinence | [residents_characteristics_40] | [residents_characteristics_28] | [residents_characteristics_29] | [residents_characteristics_30]

INFECTION CONTROL AND ANTIMICROBIAL STEWARDSHIP RESOURCES
I – Clinical governance | [infectionctrl_1] | /6 points
II – Infection control indicators | [infectionctrl_2] | /7 points
III - Hand hygiene indicators | [infectionctrl_3] | /5 points
IV- Protocols for infection control | [infectionctrl_4] | /6 points
V – Antimicrobial stewardship indicators | [infectionctrl_5] | /11 points
VI- Infection diagnosis/laboratory support | [infectionctrl_6] | /4 points
VII – Surveillance | [infectionctrl_7] | /3 points